Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation

Why is Procter & Gamble cutting 7,000 jobs? How did Boeing avoid prosecution for 737 Max crashes? What impact did Trump-Xi trade talks have on markets? Why are U.S. jobless claims rising recently? How are tariffs affecting U.S. manufacturing costs? What caused Tesla’s sales decline in China? Why did Amazon invest $10B in AI data centers?

Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation

benzinga.com/news/health-care/25/06/45755748/johnson-johnson-highlights-multiple-blood-cancer-trial-data-at-asco-presentation

Johnson & Johnson (NYSE:JNJ) shared data from several cancer studies at the 2025 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday.
Here’s that the New Brunswick, New Jersey-based company released.
Phase 3 AMPLITUDE Study
Johnson & Johnson released promising Phase 3…

This story appeared on benzinga.com, 2025-06-03 18:14:34.